A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Imetelstat (Primary) ; Antineoplastics; Corticosteroids; Danazol; Hydroxycarbamide; Interferon; Thalidomide
- Indications Myelofibrosis; Polycythaemia vera; Thrombocytosis
- Focus Registrational; Therapeutic Use
- Acronyms IMpactMF
- Sponsors Geron Corporation
Most Recent Events
- 28 May 2025 According to Geron Corporation media release, trial has met approximately 80% of its enrollment target as of February 2025.
- 28 May 2025 According to Geron Corporation media release, company announced presentation of data from this study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress.
- 13 Mar 2025 Planned End Date changed from 25 Nov 2026 to 30 Jun 2028.